Resultados: 17

Atorvastatin therapy for prevention of anthracycline-induced cardiotoxicity in cancer patients: a meta-analysis

Circulation; 150 (Suppl. 1), 2024
INTRODUCTION: Cancer therapy-induced cardiac dysfunction is a significant adverse effect of chemotherapeutic agents, particularly anthracyclines (ANT). High-potency statin therapy, such as atorvastatin, appears to exert a protective effect against this condition. OBJECTIVE: We aimed to perform a meta-ana...

HIV and cardiovascular risk: should we use other targets for cholesterol control? Brazilian data compared to major studies

Eur. heart j; 45 (Suppl. 1), 2024
In daily clinical practice, cardiologists are confronted with patients with HIV/AIDS and this population needs special attention due to their higher cardiovascular risk. Studies show an increase in cardiovascular disease (CVD) among people with HIV/AIDS and one of the main causes of death in this group. ...

Safety and efficacy of moderate-intensity statin plus ezetimibe versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease: a meta-analysis

Eur. heart j; 45 (Suppl. 1), 2024
BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD), affects approximately 18.6 million individuals worldwide, poses an important healthcare challenge. Despite the established efficacy of both high-intensity statin monotherapy (HIS) and moderate-intensity statin plus ezetimibe (MIS+EZT) in ASCVD m...

Avaliação da efetividade das estatinas de alta potência na redução do LDL em pacientes em prevenção secundária no ambulatório de dislipidemia em hospital terciário, São Paulo
Evaluation of the effectiveness of high-potency statins in reducing LDL in patients undergoing secondary prevention in the dyslipidemia outpatient clinic of a tertiary hospital, São Paulo

Arq. bras. cardiol; 121 (9 supl.1), 2024
INTRODUÇÃO: A hipercolesterolemia, em particular o aumento dos níveis de lipoproteína de baixa densidade (LDL), é um fator de risco bem estabelecido para o desenvolvimento e progressão de doenças cardiovasculares. A terapia com estatinas tem sido amplamente utilizada para reduzir os níveis de LDL...

Cardio-protective effects of statins in patients with breast cancer undergoing anthracycline-based chemotherapy: a metaanalysis of randomized controlled trials

Arq. bras. cardiol; 121 (9 supl.1), 2024
BACKGROUND: Contemporary understanding characterizes cardiotoxicity as a reduction in left ventricular ejection fraction (LVEF) by at least 10%, resulting in a final value below 53% in successive assessments. Nevertheless, breast cancer therapy can impact the cardiovascular system through various avenues...

Impact of statin therapy on mortality and recurrence in female breast cancer: a meta-analysis

Ann. oncol; 35 (Suppl. 2), 2024
BACKGROUND Breast cancer (BC) incidence is estimated to achieve over 3 million new cases and 1 million deaths by 2040. Beyond its physical toll, breast cancer detrimentally affects quality of life, imposing emotional, social, and financial burdens on patients and their families. Statins, commonly prescri...

Safety and efficacy of moderate-intensity statin plus ezetimibe versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease: a meta-analysis

J. clin. lipidol; (), 2024
BACKGROUND Atherosclerotic cardiovascular disease (ASCVD), affects approximately 18.6 million individuals worldwide and poses a significant healthcare related challenge. Despite the established efficacy of both high-intensity statin monotherapy (HIS) and moderate-intensity statin plus ezetimibe (MIS+EZT)...

Predicted deleterious variants in ABCA1, LPL, LPA and KIF6 are associated with statin response and adverse events in patients with familial hypercholesterolemia and disturb protein structure and stability

Pharmacogenet. genomics; 34 (4), 2024
OBJECTIVES: This study explored the association of deleterious variants in pharmacodynamics (PD) genes with statin response and adverse effects in patients with familial hypercholesterolemia (FH) and analyzed their potential effects on protein structure and stability. METHODS: Clinical and laboratory dat...

Cardiovascular benefits of statin plus ezetimibe combination therapy versus statin monotherapy in acute coronary syndrome: a meta-analysis of randomized controlled trials

J. Am. Coll. Cardiol; 83 (13 Suppl. A), 2024
BACKGROUND: The efficacy of adding ezetimibe to statin therapy for event reduction in patients with acute coronary syndromes (ACS) remains a topic of ongoing debate. METHODS: We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing ezetimibe plus statin versus s...

Lipidomic analysis identified potential predictive biomarkers of statin response in subjects with Familial hypercholesterolemia

Chem. Phys. lipids; 257 (), 2023
Familial hypercholesterolemia (FH) is a disorder of lipid metabolism that causes elevated low-density lipoprotein cholesterol (LDL-c) and increased premature atherosclerosis risk. Statins inhibit endogenous cholesterol biosynthesis, which reduces LDL-c plasma levels and prevent from cardiovascular events...